|
35) Over the past three months, how have the price terms (for example, financing rates) offered to nonfinancial corporations as reflected across the entire spectrum of securities financing and otc derivatives transaction types changed, regardless of nonprice terms? (5)
|
|
36) Over the past three months, how has your use of nonprice terms (for example, haircuts, maximum maturity, covenants, cure periods, cross-default provisions or other documentation features) with respect to nonfinancial corporations across the entire spectrum of securities financing and otc derivatives transaction types changed, regardless of price terms? (5)
|
|
37) To the extent that the price or nonprice terms applied to nonfinancial corporations have tightened or eased over the past three months (as reflected in your responses to questions 35 and 36), what are the most important reasons for the change? (42)
|
|
38) How has the intensity of efforts by nonfinancial corporations to negotiate more favorable price and nonprice terms changed over the past three months? (5)
|
